6976.TWO Acepodia, Inc.

Healthcare Biotechnology Taiwan OTC Exchange
11.95 TWD
Close of Nov 6, 2026
10.85 17.40
Market cap
TWD 6.97B
P/E
-
P/B
1.44x
ROE
-16.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6976.TWO undervalued?

Graham number

The Graham number of Acepodia, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Acepodia, Inc. fundamental analysis

No fundamental analysis for Acepodia, Inc. yet.

Acepodia, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Acepodia, Inc.

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.

Full company profile